Global Breast Cancer Therapy Market
Global Breast Cancer Therapy Market

Breast Cancer Therapy Comprehensive Study by Type (Targeted Therapy, Hormonal Therapy, Chemotherapy, Radiation Therapy, Immunotherapy), Application (Hospitals, Ambulatory Surgical Centers, Clinics, Retail Pharmacies), Factors for Treatment (Type of Breast Cancer, Size of the Tumor, Stage of Breast Cancer, Grade of Cancer Cells), Mechanism (Local Therapy, Systemic Therapy, Adjuvant Therapy, Neoadjuvant Therapy) Players and Region - Global Market Outlook to 2025

Breast Cancer Therapy Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Oct 2020 Edition 246 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Breast Cancer Therapy Market Scope?
Breast cancer is known worldwide as the most common cancer in women. It is a common misconception that breast cancer is viewed as a disease of the developed world. Breast cancer is a cancerous manifestation of breast tissue and is the most common cancer in women worldwide. There are about a million new cases of breast cancer each year. Breast cancer accounts for about 10% of global cancer. The awareness of the impact on survival rates in the case of early diagnosis has increased significantly. The high incidence rate of breast cancer is now becoming an issue and several drug companies are increasingly investing in breast cancer research. Breast cancer is a tumor found in breast tissue. A lump can usually be seen in the chest it shows symptoms such as changes in shape, a newly turned nipple, or a red or scaly patch of skin and fluid coming off the nipple. The WHO had stated that breast cancer affects around 2.1 million women each year and is the leading cause of malignancy-related deaths. Breast cancer is one of the leading causes of death among Singaporean women. Singapore has one of the highest age-adjusted breast cancer incidences in Asia, with an increasing incidence in women in their fifties. Mammography screening in Singaporean women increases the detection rate of early-stage breast cancer with acceptable recall and needle biopsy rates.

The market study is being classified by Type (Targeted Therapy, Hormonal Therapy, Chemotherapy, Radiation Therapy and Immunotherapy), by Application (Hospitals, Ambulatory Surgical Centers, Clinics and Retail Pharmacies) and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Breast Cancer Therapy market throughout the predicted period.

Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (United States), Merck & Co. (United States), AstraZeneca (United Kingdom), Novartis AG (Switzerland), Astellas Pharma Inc. (Japan), Eli Lilly and Company (United States), Eisai Co., Ltd. (Japan), AbbVie, Inc. (United States) and Janssen Global Services LLC (United States) are some of the key players profiled in the study.

Segmentation Analysis
AdvanceMarketAnalytics has segmented the market of Global Breast Cancer Therapy market by Type, Application and Region.

On the basis of geography, the market of Breast Cancer Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Pfizer Inc., in the year 2019, had launched product IBRANCE. The studies proved the effectiveness of IBRANCE combination therapy for certain patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) b and for metastatic breast cancer (MBC). These studies were also presented in the European Society for Medical Oncology (ESMO) Congress Barcelona in Spain.
US Food and Drug Administration (FDA), in the year 2019, approved the first treatment for a certain type of mammary carcinoma produced by an inherited genetic mutation. Piqray (alpelisib) is a targeted therapy called a PI3K inhibitor. Itís precisely used for advanced breast cancer patientís postmenopausal women, and men Ė whose tumors have the PIK3CA mutation and hormone receptor are (HR) positive and HER2 negative the drug is meant to be used along with Faslodex (fulvestrant), a hormone therapy already approved by the FDA. Recently U.S Food & Drug Administration has approved CDK4/6 inhibitors like abemaciclib, palbociclib, and it was proved to be beneficial in stage 4 cancer and has become a standard treatment in mammary carcinoma.

Influencing Market Trend
  • Short Breast-Feeding Timeframe
  • Rising Prevalence of Obesity in Women after Menopause
  • Rising Use of Hormone Replacement Therapy (HRT) and Oral Birth Control Pills Resulting In Increased Levels of Oestrogen

Market Drivers
  • Increasing Breast Cancer Prevalence in the Developed Countries
  • Growing Awareness Regarding Breast Cancer
  • Increasing Rate of Alcohol Consumption in Women
  • Rising Shift towards Adoption of Western Lifestyle

Opportunities
  • Growing Exposure to Certain Carcinogens and Endocrine Disruptors
  • Advancements in Cancer Biology
  • Launch of Several Diagnostic and Screening Programs Worldwide

Restraints
  • Favorable Insurance and Reimbursement Policies
  • High Cost of Breast Cancer Therapeutics

Challenges
  • Severe Adverse Effects Associated With the Therapy
  • Difficulty in Diagnosis


Key Target Audience
Providers of Breast Cancer Therapy, End-Users, Potential Investors, Market Research Firms and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Targeted Therapy
  • Hormonal Therapy
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Retail Pharmacies
By Factors for Treatment
  • Type of Breast Cancer
  • Size of the Tumor
  • Stage of Breast Cancer
  • Grade of Cancer Cells

By Mechanism
  • Local Therapy
  • Systemic Therapy
  • Adjuvant Therapy
  • Neoadjuvant Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Breast Cancer Prevalence in the Developed Countries
      • 3.2.2. Growing Awareness Regarding Breast Cancer
      • 3.2.3. Increasing Rate of Alcohol Consumption in Women
      • 3.2.4. Rising Shift towards Adoption of Western Lifestyle
    • 3.3. Market Challenges
      • 3.3.1. Severe Adverse Effects Associated With the Therapy
      • 3.3.2. Difficulty in Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Short Breast-Feeding Timeframe
      • 3.4.2. Rising Prevalence of Obesity in Women after Menopause
      • 3.4.3. Rising Use of Hormone Replacement Therapy (HRT) and Oral Birth Control Pills Resulting In Increased Levels of Oestrogen
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Breast Cancer Therapy, by Type, Application, Factors for Treatment, Mechanism and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Breast Cancer Therapy (Value)
      • 5.2.1. Global Breast Cancer Therapy by: Type (Value)
        • 5.2.1.1. Targeted Therapy
        • 5.2.1.2. Hormonal Therapy
        • 5.2.1.3. Chemotherapy
        • 5.2.1.4. Radiation Therapy
        • 5.2.1.5. Immunotherapy
      • 5.2.2. Global Breast Cancer Therapy by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Clinics
        • 5.2.2.4. Retail Pharmacies
      • 5.2.3. Global Breast Cancer Therapy by: Factors for Treatment (Value)
        • 5.2.3.1. Type of Breast Cancer
        • 5.2.3.2. Size of the Tumor
        • 5.2.3.3. Stage of Breast Cancer
        • 5.2.3.4. Grade of Cancer Cells
      • 5.2.4. Global Breast Cancer Therapy by: Mechanism (Value)
        • 5.2.4.1. Local Therapy
        • 5.2.4.2. Systemic Therapy
        • 5.2.4.3. Adjuvant Therapy
        • 5.2.4.4. Neoadjuvant Therapy
      • 5.2.5. Global Breast Cancer Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Breast Cancer Therapy (Price)
      • 5.3.1. Global Breast Cancer Therapy by: Type (Price)
  • 6. Breast Cancer Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Astellas Pharma Inc. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eisai Co., Ltd. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Janssen Global Services LLC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Breast Cancer Therapy Sale, by Type, Application, Factors for Treatment, Mechanism and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Breast Cancer Therapy (Value)
      • 7.2.1. Global Breast Cancer Therapy by: Type (Value)
        • 7.2.1.1. Targeted Therapy
        • 7.2.1.2. Hormonal Therapy
        • 7.2.1.3. Chemotherapy
        • 7.2.1.4. Radiation Therapy
        • 7.2.1.5. Immunotherapy
      • 7.2.2. Global Breast Cancer Therapy by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Clinics
        • 7.2.2.4. Retail Pharmacies
      • 7.2.3. Global Breast Cancer Therapy by: Factors for Treatment (Value)
        • 7.2.3.1. Type of Breast Cancer
        • 7.2.3.2. Size of the Tumor
        • 7.2.3.3. Stage of Breast Cancer
        • 7.2.3.4. Grade of Cancer Cells
      • 7.2.4. Global Breast Cancer Therapy by: Mechanism (Value)
        • 7.2.4.1. Local Therapy
        • 7.2.4.2. Systemic Therapy
        • 7.2.4.3. Adjuvant Therapy
        • 7.2.4.4. Neoadjuvant Therapy
      • 7.2.5. Global Breast Cancer Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Breast Cancer Therapy (Price)
      • 7.3.1. Global Breast Cancer Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Breast Cancer Therapy: by Type(USD Million)
  • Table 2. Breast Cancer Therapy Targeted Therapy , by Region USD Million (2014-2019)
  • Table 3. Breast Cancer Therapy Hormonal Therapy , by Region USD Million (2014-2019)
  • Table 4. Breast Cancer Therapy Chemotherapy , by Region USD Million (2014-2019)
  • Table 5. Breast Cancer Therapy Radiation Therapy , by Region USD Million (2014-2019)
  • Table 6. Breast Cancer Therapy Immunotherapy , by Region USD Million (2014-2019)
  • Table 7. Breast Cancer Therapy: by Application(USD Million)
  • Table 8. Breast Cancer Therapy Hospitals , by Region USD Million (2014-2019)
  • Table 9. Breast Cancer Therapy Ambulatory Surgical Centers , by Region USD Million (2014-2019)
  • Table 10. Breast Cancer Therapy Clinics , by Region USD Million (2014-2019)
  • Table 11. Breast Cancer Therapy Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 12. Breast Cancer Therapy: by Factors for Treatment(USD Million)
  • Table 13. Breast Cancer Therapy Type of Breast Cancer , by Region USD Million (2014-2019)
  • Table 14. Breast Cancer Therapy Size of the Tumor , by Region USD Million (2014-2019)
  • Table 15. Breast Cancer Therapy Stage of Breast Cancer , by Region USD Million (2014-2019)
  • Table 16. Breast Cancer Therapy Grade of Cancer Cells , by Region USD Million (2014-2019)
  • Table 17. Breast Cancer Therapy: by Mechanism(USD Million)
  • Table 18. Breast Cancer Therapy Local Therapy , by Region USD Million (2014-2019)
  • Table 19. Breast Cancer Therapy Systemic Therapy , by Region USD Million (2014-2019)
  • Table 20. Breast Cancer Therapy Adjuvant Therapy , by Region USD Million (2014-2019)
  • Table 21. Breast Cancer Therapy Neoadjuvant Therapy , by Region USD Million (2014-2019)
  • Table 22. South America Breast Cancer Therapy, by Country USD Million (2014-2019)
  • Table 23. South America Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 24. South America Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 25. South America Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 26. South America Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 27. Brazil Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 28. Brazil Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 29. Brazil Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 30. Brazil Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 31. Argentina Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 32. Argentina Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 33. Argentina Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 34. Argentina Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 35. Rest of South America Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 36. Rest of South America Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 37. Rest of South America Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 38. Rest of South America Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 39. Asia Pacific Breast Cancer Therapy, by Country USD Million (2014-2019)
  • Table 40. Asia Pacific Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 41. Asia Pacific Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 42. Asia Pacific Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 43. Asia Pacific Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 44. China Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 45. China Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 46. China Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 47. China Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 48. Japan Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 49. Japan Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 50. Japan Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 51. Japan Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 52. India Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 53. India Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 54. India Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 55. India Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 56. South Korea Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 57. South Korea Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 58. South Korea Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 59. South Korea Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 60. Taiwan Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 61. Taiwan Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 62. Taiwan Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 63. Taiwan Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 64. Australia Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 65. Australia Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 66. Australia Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 67. Australia Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 71. Rest of Asia-Pacific Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 72. Europe Breast Cancer Therapy, by Country USD Million (2014-2019)
  • Table 73. Europe Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 74. Europe Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 75. Europe Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 76. Europe Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 77. Germany Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 78. Germany Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 79. Germany Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 80. Germany Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 81. France Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 82. France Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 83. France Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 84. France Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 85. Italy Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 86. Italy Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 87. Italy Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 88. Italy Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 89. United Kingdom Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 90. United Kingdom Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 91. United Kingdom Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 92. United Kingdom Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 93. Netherlands Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 94. Netherlands Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 95. Netherlands Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 96. Netherlands Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 97. Rest of Europe Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 98. Rest of Europe Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 99. Rest of Europe Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 100. Rest of Europe Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 101. MEA Breast Cancer Therapy, by Country USD Million (2014-2019)
  • Table 102. MEA Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 103. MEA Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 104. MEA Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 105. MEA Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 106. Middle East Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 107. Middle East Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 108. Middle East Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 109. Middle East Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 110. Africa Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 111. Africa Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 112. Africa Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 113. Africa Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 114. North America Breast Cancer Therapy, by Country USD Million (2014-2019)
  • Table 115. North America Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 116. North America Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 117. North America Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 118. North America Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 119. United States Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 120. United States Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 121. United States Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 122. United States Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 123. Canada Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 124. Canada Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 125. Canada Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 126. Canada Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 127. Mexico Breast Cancer Therapy, by Type USD Million (2014-2019)
  • Table 128. Mexico Breast Cancer Therapy, by Application USD Million (2014-2019)
  • Table 129. Mexico Breast Cancer Therapy, by Factors for Treatment USD Million (2014-2019)
  • Table 130. Mexico Breast Cancer Therapy, by Mechanism USD Million (2014-2019)
  • Table 131. Breast Cancer Therapy: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Breast Cancer Therapy: by Type(USD Million)
  • Table 143. Breast Cancer Therapy Targeted Therapy , by Region USD Million (2020-2025)
  • Table 144. Breast Cancer Therapy Hormonal Therapy , by Region USD Million (2020-2025)
  • Table 145. Breast Cancer Therapy Chemotherapy , by Region USD Million (2020-2025)
  • Table 146. Breast Cancer Therapy Radiation Therapy , by Region USD Million (2020-2025)
  • Table 147. Breast Cancer Therapy Immunotherapy , by Region USD Million (2020-2025)
  • Table 148. Breast Cancer Therapy: by Application(USD Million)
  • Table 149. Breast Cancer Therapy Hospitals , by Region USD Million (2020-2025)
  • Table 150. Breast Cancer Therapy Ambulatory Surgical Centers , by Region USD Million (2020-2025)
  • Table 151. Breast Cancer Therapy Clinics , by Region USD Million (2020-2025)
  • Table 152. Breast Cancer Therapy Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 153. Breast Cancer Therapy: by Factors for Treatment(USD Million)
  • Table 154. Breast Cancer Therapy Type of Breast Cancer , by Region USD Million (2020-2025)
  • Table 155. Breast Cancer Therapy Size of the Tumor , by Region USD Million (2020-2025)
  • Table 156. Breast Cancer Therapy Stage of Breast Cancer , by Region USD Million (2020-2025)
  • Table 157. Breast Cancer Therapy Grade of Cancer Cells , by Region USD Million (2020-2025)
  • Table 158. Breast Cancer Therapy: by Mechanism(USD Million)
  • Table 159. Breast Cancer Therapy Local Therapy , by Region USD Million (2020-2025)
  • Table 160. Breast Cancer Therapy Systemic Therapy , by Region USD Million (2020-2025)
  • Table 161. Breast Cancer Therapy Adjuvant Therapy , by Region USD Million (2020-2025)
  • Table 162. Breast Cancer Therapy Neoadjuvant Therapy , by Region USD Million (2020-2025)
  • Table 163. South America Breast Cancer Therapy, by Country USD Million (2020-2025)
  • Table 164. South America Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 165. South America Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 166. South America Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 167. South America Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 168. Brazil Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 169. Brazil Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 170. Brazil Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 171. Brazil Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 172. Argentina Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 173. Argentina Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 174. Argentina Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 175. Argentina Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 176. Rest of South America Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 177. Rest of South America Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 178. Rest of South America Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 179. Rest of South America Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 180. Asia Pacific Breast Cancer Therapy, by Country USD Million (2020-2025)
  • Table 181. Asia Pacific Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 182. Asia Pacific Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 183. Asia Pacific Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 184. Asia Pacific Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 185. China Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 186. China Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 187. China Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 188. China Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 189. Japan Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 190. Japan Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 191. Japan Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 192. Japan Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 193. India Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 194. India Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 195. India Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 196. India Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 197. South Korea Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 198. South Korea Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 199. South Korea Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 200. South Korea Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 201. Taiwan Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 202. Taiwan Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 203. Taiwan Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 204. Taiwan Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 205. Australia Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 206. Australia Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 207. Australia Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 208. Australia Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 209. Rest of Asia-Pacific Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 210. Rest of Asia-Pacific Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 211. Rest of Asia-Pacific Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 212. Rest of Asia-Pacific Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 213. Europe Breast Cancer Therapy, by Country USD Million (2020-2025)
  • Table 214. Europe Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 215. Europe Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 216. Europe Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 217. Europe Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 218. Germany Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 219. Germany Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 220. Germany Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 221. Germany Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 222. France Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 223. France Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 224. France Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 225. France Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 226. Italy Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 227. Italy Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 228. Italy Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 229. Italy Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 230. United Kingdom Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 231. United Kingdom Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 232. United Kingdom Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 233. United Kingdom Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 234. Netherlands Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 235. Netherlands Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 236. Netherlands Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 237. Netherlands Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 238. Rest of Europe Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 239. Rest of Europe Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 240. Rest of Europe Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 241. Rest of Europe Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 242. MEA Breast Cancer Therapy, by Country USD Million (2020-2025)
  • Table 243. MEA Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 244. MEA Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 245. MEA Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 246. MEA Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 247. Middle East Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 248. Middle East Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 249. Middle East Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 250. Middle East Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 251. Africa Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 252. Africa Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 253. Africa Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 254. Africa Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 255. North America Breast Cancer Therapy, by Country USD Million (2020-2025)
  • Table 256. North America Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 257. North America Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 258. North America Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 259. North America Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 260. United States Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 261. United States Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 262. United States Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 263. United States Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 264. Canada Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 265. Canada Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 266. Canada Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 267. Canada Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 268. Mexico Breast Cancer Therapy, by Type USD Million (2020-2025)
  • Table 269. Mexico Breast Cancer Therapy, by Application USD Million (2020-2025)
  • Table 270. Mexico Breast Cancer Therapy, by Factors for Treatment USD Million (2020-2025)
  • Table 271. Mexico Breast Cancer Therapy, by Mechanism USD Million (2020-2025)
  • Table 272. Breast Cancer Therapy: by Type(USD/Units)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Breast Cancer Therapy: by Type USD Million (2014-2019)
  • Figure 5. Global Breast Cancer Therapy: by Application USD Million (2014-2019)
  • Figure 6. Global Breast Cancer Therapy: by Factors for Treatment USD Million (2014-2019)
  • Figure 7. Global Breast Cancer Therapy: by Mechanism USD Million (2014-2019)
  • Figure 8. South America Breast Cancer Therapy Share (%), by Country
  • Figure 9. Asia Pacific Breast Cancer Therapy Share (%), by Country
  • Figure 10. Europe Breast Cancer Therapy Share (%), by Country
  • Figure 11. MEA Breast Cancer Therapy Share (%), by Country
  • Figure 12. North America Breast Cancer Therapy Share (%), by Country
  • Figure 13. Global Breast Cancer Therapy: by Type USD/Units (2014-2019)
  • Figure 14. Global Breast Cancer Therapy share by Players 2019 (%)
  • Figure 15. Global Breast Cancer Therapy share by Players (Top 3) 2019(%)
  • Figure 16. Global Breast Cancer Therapy share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 22. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co. (United States) Revenue: by Geography 2019
  • Figure 24. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. AstraZeneca (United Kingdom) Revenue: by Geography 2019
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 28. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Astellas Pharma Inc. (Japan) Revenue: by Geography 2019
  • Figure 30. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 32. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Eisai Co., Ltd. (Japan) Revenue: by Geography 2019
  • Figure 34. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. AbbVie, Inc. (United States) Revenue: by Geography 2019
  • Figure 36. Janssen Global Services LLC (United States) Revenue, Net Income and Gross profit
  • Figure 37. Janssen Global Services LLC (United States) Revenue: by Geography 2019
  • Figure 38. Global Breast Cancer Therapy: by Type USD Million (2020-2025)
  • Figure 39. Global Breast Cancer Therapy: by Application USD Million (2020-2025)
  • Figure 40. Global Breast Cancer Therapy: by Factors for Treatment USD Million (2020-2025)
  • Figure 41. Global Breast Cancer Therapy: by Mechanism USD Million (2020-2025)
  • Figure 42. South America Breast Cancer Therapy Share (%), by Country
  • Figure 43. Asia Pacific Breast Cancer Therapy Share (%), by Country
  • Figure 44. Europe Breast Cancer Therapy Share (%), by Country
  • Figure 45. MEA Breast Cancer Therapy Share (%), by Country
  • Figure 46. North America Breast Cancer Therapy Share (%), by Country
  • Figure 47. Global Breast Cancer Therapy: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer Inc. (United States)
  • Merck & Co. (United States)
  • AstraZeneca (United Kingdom)
  • Novartis AG (Switzerland)
  • Astellas Pharma Inc. (Japan)
  • Eli Lilly and Company (United States)
  • Eisai Co., Ltd. (Japan)
  • AbbVie, Inc. (United States)
  • Janssen Global Services LLC (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation